 | Up a level |
Kovari, H; Surial, B; Tarr, P E; Cavassini, M; Calmy, A; Schmid, P; Bernasconi, E; Rauch, A; Wandeler, G; Ledergerber, B (2021). Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study. HIV medicine, 22(7), pp. 623-628. Wiley 10.1111/hiv.13106
Laut, K; Kirk, O; Rockstroh, J; Phillips, A; Ledergerber, B; Gatell, J; Gazzard, B; Horban, A; Karpov, I; Losso, M; d'Arminio Monforte, A; Pedersen, C; Ristola, M; Reiss, P; Scherrer, A U; de Wit, S; Aho, I; Rasmussen, L D; Svedhem, V; Wandeler, Gilles; ... (2020). The EuroSIDA study: 25 years of scientific achievements. HIV medicine, 21(2), pp. 71-83. Blackwell Science 10.1111/hiv.12810
Hachfeld, Anna; Darling, K; Calmy, A; Ledergerber, B; Weber, R; Battegay, M; Wissel, K; Di Benedetto, C; Fux, C A; Tarr, P E; Kouyos, R; Ruggia, LS; Furrer, Hansjakob; Wandeler, Gilles (2019). Why do sub-Saharan Africans present late for HIV care in Switzerland? HIV medicine, 20(6), pp. 418-423. Blackwell Science 10.1111/hiv.12727
Hasse, Barbara; Tarr, Philip E; Marques-Vidal, Pedro; Waeber, Gerard; Preisig, Martin; Mooser, Vincent; Valeri, Fabio; Djalali, Sima; Rauch, Andri; Bernasconi, Enos; Calmy, Alexandra; Cavassini, Matthias; Vernazza, Pietro; Battegay, Manuel; Weber, Rainer; Senn, Oliver; Vollenweider, Peter; Ledergerber, Bruno; Aubert, V; Barth, J; ... (2015). Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infectious Diseases, 2(3), ofv108. Oxford University Press 10.1093/ofid/ofv108
Schaerer, V; Haubitz, Sebastian; Kovari, H; Ledergerber, B; Ambrosioni, J; Cavassini, M; Stoeckle, M; Schmid, P; Decosterd, L; Aouri, M; Böni, J; Günthard, H F; Furrer, Hansjakob; Metzner, K J; Fehr, J; Rauch, Andri (2015). Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV medicine, 16(10), pp. 599-607. Blackwell Science 10.1111/hiv.12269
Kouyos, Roger D; Hasse, Barbara; Calmy, Alexandra; Cavassini, Matthias; Furrer, Hansjakob; Stöckle, Marcel; Vernazza, Pietro L; Bernasconi, Enos; Weber, Rainer; Günthard, Huldrych F; Aubert, V; Battegay, M; Bernasconi, E; Böni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Dollenmaier, G; Egger, M; ... (2015). Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2(2), ofv077. Oxford University Press 10.1093/ofid/ofv077
Weber, R; Huber, M; Battegay, M; Stähelin, Cornelia Johanna; Castro Batanjer, E; Calmy, A; Bregenzer, A; Bernasconi, E; Schoeni-Affolter, F; Ledergerber, B (2015). Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. HIV medicine, 16(3), pp. 137-151. Blackwell Science 10.1111/hiv.12184
Braun, DL; Rauch, Andri; Durisch, N; Eberhard, N; Anagnostopoulos, A; Ledergerber, B; Metzner, KJ; Böni, J; Weber, R; Fehr, J (2014). Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. HIV medicine, 15(10), pp. 625-630. Blackwell Science 10.1111/hiv.12166
Thierfelder, C; Weber, R; Elzi, L; Furrer, H; Cavassini, M; Calmy, A; Bernasconi, E; Gutmann, C; Ledergerber, B; Swiss HIV Cohort Study Group, (2012). Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. HIV medicine, 13(2), pp. 118-26. Oxford: Blackwell Science 10.1111/j.1468-1293.2011.00949.x
Huber, M; Ledergerber, B; Sauter, R; Young, J; Fehr, J; Cusini, A; Battegay, M; Calmy, A; Orasch, C; Nicca, D; Bernasconi, E; Jaccard, R; Held, L; Weber, R; Swiss HIV Cohort Study Group, (2012). Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV medicine, 13(7), pp. 387-397. Oxford: Blackwell Science 10.1111/j.1468-1293.2011.00984.x
Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, Hansjakob; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Swiss HIV Cohort Study, (SHCS) (2012). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV medicine, 14(4), pp. 195-207. Oxford: Blackwell Science 10.1111/j.1468-1293.2012.01051.x
Sambatakou, H; Dabis, F; Geffard, S; Smit, C; de Wolf, F; van der Meer, J; Peters, L; Puoti, M; Monforte, AD; Tural, C; Zinkernagel, A; Ledergerber, B; Rauch, A; de Witt, S; Suarez-Lozano, N (2012). Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration. Antiviral therapy, 17(8), pp. 1541-50. London: International Medical Press
Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R; Swiss HIV Cohort Study (SHCS), (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 279-88. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00880.x
Franceschi, S; Lise, M; Clifford, G M; Rickenbach, M; Levi, F; Maspoli, M; Bouchardy, C; Dehler, S; Jundt, G; Ess, S; Bordoni, A; Konzelmann, I; Frick, H; Dal Maso, L; Elzi, L; Furrer, H; Calmy, A; Cavassini, M; Ledergerber, B and Keiser, O (2010). Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. British journal of cancer, 103(3), pp. 416-422. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6605756
Flammer, A.J.; T.Vo, N.T.; Ledergerber, B; Hermann, F; Gamperli, A; Huttner, A; Evison, J; Baumgartner, I; Cavassini, M; Hayoz, D.; Quitzau, K; Hersberger, M; Sudano, I; Ruschitzka, F; Luscher, T.F.; Noll, G; Weber, R. (2009). Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart, 95(5), pp. 385-90. London: BMJ Publishing Group 10.1136/hrt.2007.137646
Weber, R; Huber, M; Rickenbach, M; Furrer, H; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Ledergerber, B (2009). Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV medicine, 10(7), pp. 407-16. Oxford: Blackwell Science 10.1111/j.1468-1293.2009.00701.x
Combescure, Christophe; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV medicine, 10(8), pp. 470-6. Oxford: Blackwell Science 10.1111/j.1468-1293.2009.00714.x
May, M; Sterne, JA; Sabin, C; Costagliola, D; Justice, AC; Thiébaut, R; Gill, J; Phillips, A; Reiss, P; Hogg, R; Ledergerber, B; D'Arminio Monforte, A; Schmeisser, N; Staszewski, S; Antiretroviral, Therapy (ART) Cohort Collaboration (2007). Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS, 21(9), pp. 1185-1197. Hagerstown, Md.: Lippincott Williams & Wilkins
Sterne, JA; May, M; Bucher, HC; Ledergerber, B; Furrer, H; Cavassini, M; Bernasconi, E; Hirschel, B; Egger, M; Swiss, HIV Cohort (2007). HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. Journal of internal medicine, 261(3), pp. 255-67. Oxford: Blackwell Scientific Publications 10.1111/j.1365-2796.2006.01761.x
Ledergerber, B; Furrer, H; Rickenbach, M; Lehmann, R; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Egger, M; Weber, R; Swiss, HIV Cohort Study (2007). Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clinical infectious diseases, 45(1), pp. 111-9. Cary, N.C.: The University of Chicago Press 10.1086/518619
von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, PL; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, HF; for, the Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of internal medicine, 167(16), pp. 1782-90. Chicago, Ill.: American Medical Association 10.1001/archinte.167.16.1782
Zinkernagel, AS; von Wyl, V; Ledergerber, B; Rickenbach, M; Furrer, H; Battegay, M; Hirschel, B; Tarr, PE; Opravil, M; Bernasconi, E; Schmid, P; Weber, R; Swiss, HIV Cohort Study (2006). Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy, 11(2), pp. 131-42. London: International Medical Press
Müller, V; Ledergerber, B; Perrin, L; Klimkait, T; Furrer, H; Telenti, A; Bernasconi, E; Vernazza, P; Günthard, HF; Bonhoeffer, S; Swiss, HIV Cohort Study (2006). Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS, 20(6), pp. 889-94. Hagerstown, Md.: Lippincott Williams & Wilkins
Franceschi, S; Polesel, J; Rickenbach, M; Dal Maso, L; Probst-Hensch, N M; Fux, C; Cavassini, M; Hasse, B; Kofler, A; Ledergerber, B; Erb, P; Clifford, G M (2006). Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study. British journal of cancer, 95(11), pp. 1598-602. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6603472
Karrer, U; Ledergerber, B; Furrer, H; Elzi, L; Battegay, M; Cavassini, M; Gayet-Ageron, A; Hirschel, B; Schmid, P; Russotti, M; Weber, R; Speck, RF; Swiss, HIV Cohort Study (2005). Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS, 19(17), pp. 1987-94. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000194136.73876.9c
Kaufmann, GR; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M; Swiss, HIV Cohort Study (2005). Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases, 41(3), pp. 361-72. Cary, N.C.: The University of Chicago Press 10.1086/431484
Tarr, PE; Taffé, P; Bleiber, G; Furrer, H; Rotger, M; Martinez, R; Hirschel, B; Battegay, M; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Rickenbach, M; Ledergerber, B; Telenti, A; Swiss, HIV Cohort Study (2005). Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. Journal of infectious diseases, 191(9), pp. 1419-26. Cary, N.C.: The University of Chicago Press 10.1086/429295
Jost, J; Ledergerber, B; Täuber, MG (1986). [The HIV-antibody positive patient in general practice. Guidelines for rational diagnosis and treatment]. Praxis - schweizerische Rundschau für Medizin, 75(48), pp. 1454-7. Bern: Huber
